<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>(1) Thalidomide is highly teratogenic </plain></SENT>
<SENT sid="1" pm="."><plain>It can also cause irreversible <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>(2) In type II lepra reactions evidence of efficacy at a dose of 400 mg/day is based on a few relatively old comparative trials and above <z:hpo ids='HP_0000001'>all</z:hpo> a review of more than 4,500 cases </plain></SENT>
<SENT sid="3" pm="."><plain>Most patients feel a benefit within 24-48 hours after beginning the treatment, but most also require lengthy treatment at a reduced dose (25-100 mg/day) to avoid relapses </plain></SENT>
<SENT sid="4" pm="."><plain>(3) Two placebo-controlled trials involving a total of 130 patients have shown the efficacy of thalidomide in the treatment of severe recurrent aphthous disease </plain></SENT>
<SENT sid="5" pm="."><plain>(4) In Jessner-Kanoff disease, a mild condition, the efficacy of thalidomide has been shown in a single placebo-controlled trial </plain></SENT>
<SENT sid="6" pm="."><plain>(5) In <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e>, non comparative trials have shown remission from <z:mp ids='MP_0001212'>skin lesions</z:mp> in patients resistant to previous treatments </plain></SENT>
<SENT sid="7" pm="."><plain>(6) In the curative treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> in bone marrow graft recipients, thalidomide has been assessed only in non comparative trials involving a few dozens of patients </plain></SENT>
</text></document>